Exosome production promoter
By inhibiting acidic ceramidase to increase ceramide levels, exosome production is promoted, effectively addressing the lack of treatments for Alzheimer's disease by enhancing amyloid-β protein removal.
Patent Information
- Application Number
- JP2019216505
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2019-11-29
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2039-11-29
AI Technical Summary
Current treatments for Alzheimer's disease focus on suppressing amyloid-β protein accumulation, but drugs that promote exosome production to aid in this process have not been sufficiently investigated.
Inhibiting the function or suppressing the expression of acidic ceramidase, particularly using substances like N-oleylethanolamine, to increase endogenous ceramide levels, thereby promoting exosome production, which are involved in amyloid-β protein removal.
Efficiently increasing exosome production leads to enhanced amyloid-β protein degradation, potentially preventing and treating Alzheimer's disease.
Smart Images

Figure 0007594358000007 
Figure 0007594358000008 
Figure 0007594358000009
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent capable of promoting the production of exosomes. [Background technology]
[0002] Currently, Alzheimer's disease is a neurodegenerative disease that accounts for more than half of the causes of dementia, and there is a need to establish treatment and prevention methods. Research to date has made progress in elucidating the pathological mechanism of Alzheimer's disease, and it is believed that one of the key points for preventing, slowing down the progression of, and improving Alzheimer's disease is to suppress the accumulation of amyloid beta protein, which is at the center of the pathological mechanism.
[0003] Drugs that suppress the accumulation of amyloid β protein have been widely studied. For example, Patent Document 1 discloses an inhibitor that suppresses the formation of amyloid fibrils, including a water-soluble peptide metal complex array. For example, Patent Document 2 discloses a composition for inhibiting the aggregation of amyloid β protein, which contains an extract of perilla as an active ingredient. For example, Patent Document 3 discloses an inhibitor of amyloid β aggregation caused by GNE gene mutation, which contains at least one of N-acetylneuraminic acid, N-acetylmannosamine, and sialyllactose.
[0004] Recent research suggests that exosomes may be involved in the metabolism of amyloid β protein in the brain and the onset and progression of Alzheimer's disease. Exosomes are membrane vesicles with a diameter of 30 to 200 nm that are surrounded by a lipid bilayer membrane and are secreted from cells. They encapsulate nucleic acids such as mRNA and miRNA, as well as proteins, and function as carriers of intercellular communication.
[0005] It is believed that amyloid β protein is transferred to microglia via exosomes and then degraded. For example, Non-Patent Document 1 suggests that neuron-derived exosomes highly express amyloid β-binding glycolipids, have the ability to capture amyloid β protein, and have the ability to remove amyloid β protein in cooperation with phagocyte microglia in the brain. In addition, Non-Patent Document 2 suggests that neuron-derived exosomes capture amyloid β on their surface and transport it to microglia, thereby increasing the efficiency of decomposition of amyloid β protein. In addition, for example, Non-Patent Document 3 suggests that the secretion of exosomes promotes the removal function of amyloid β protein by microglia. In addition, for example, Non-Patent Document 4 suggests that exosomes are involved in the metabolism of amyloid β in the brain. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] JP 2016-145175 A [Patent Document 2] JP 2016-124865 A [Patent Document 3] JP 2014-224132 A [Non-patent literature]
[0007] [Non-Patent Document 1] Monthly "Cells", New Science Publishing, 2016, 48(1), pp. 44-47 [Non-Patent Document 2] Dementia Japan 30,Vol.30,No.3,358-367(2016) [Non-Patent Document 3] Yuyama K et al., J Biol Chem., 289(35), 24488-98(2014) [Non-Patent Document 4] Yuyama K et al., J Biol Chem., 287(14), 10977-89(2012) Summary of the Invention [Problem to be solved by the invention]
[0008] Thus, exosomes are known to be involved in the removal and suppression of the accumulation of amyloid β protein. Therefore, promoting the production of exosomes can suppress the accumulation of amyloid β protein and is thought to be effective in the prevention and treatment of Alzheimer's disease.
[0009] However, drugs that can promote exosome production have not yet been thoroughly investigated.
[0010] In light of the above-mentioned current situation, the present inventor, in searching for an exosome production promoter that can easily promote exosome production in vivo, added sphingolipids of various chain lengths, which have different carbon numbers of fatty acids bound to the phingoid moiety, to SH-SY5Y derived from human neuroblastoma cells, which is an exosome standard, and recovered exosomes from the culture supernatant. It was found that when ceramide was added, more exosomes could be recovered than in the control. In particular, when C6 ceramide and C18 ceramide were added, the amount of exosomes recovered was large, and the amount of exosomes recovered was at the same level. In other words, it was found that C6 ceramide and C18 ceramide have particularly excellent exosome production promoting ability.
[0011] In order to search for an exosome production promoter that can more efficiently promote the production of exosomes in the body, the present inventors focused on inhibiting the function and / or suppressing the expression of ceramidase in order to produce exosomes by increasing endogenous ceramide.
[0012] Ceramidase is an enzyme that cleaves fatty acids from ceramide to produce sphingosine, and is classified into acidic ceramidase (localized in lysosomes, optimal pH: 4.5), neutral ceramidase (localized in cell membrane, optimal pH: 7.0), and alkaline ceramidase (localized in endoplasmic reticulum or Golgi apparatus, optimal pH: 8.5-9.5) according to its intracellular localization site and optimal pH. However, it is not known which ceramidase is effective in efficiently increasing endogenous ceramide that can efficiently promote exosome production.
[0013] Therefore, an object of the present invention is to provide a technique for efficiently increasing endogenous ceramide in order to efficiently promote exosome acidification. [Means for solving the problem]
[0014] As a result of intensive research, the present inventors have found that by functionally inhibiting or suppressing the expression of acid ceramidase, which is one of ceramidases, endogenous long-chain ceramides can be efficiently increased to promote exosome production. The reason for such excellent effects is that long-chain ceramides such as C18 ceramide are localized in lysosomes, while short-chain ceramides such as C6 ceramide do not show such a localization mode. Therefore, it is considered that by targeting acid ceramidase localized in lysosomes for functional inhibition or expression inhibition, the endogenous ceramide can be selectively increased by increasing the localized long-chain ceramide among endogenous ceramides, thereby enabling an efficient increase in endogenous ceramide. Furthermore, the present invention has also found that lysosome-associated transmembrane protein 4B (LAPTM4B) is involved in the promotion of exosome production caused by functional inhibition or expression inhibition of acid ceramidase. The present invention was completed through further research based on these findings.
[0015] That is, the present invention provides the following aspects. Item 1. An exosome production promoter comprising as an active ingredient a substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase. Item 2. The exosome production promoter according to Item 1, wherein the substance capable of functionally inhibiting acid ceramidase is at least one selected from the group consisting of a low molecular weight compound that functionally inhibits acid ceramidase, an antibody against acid ceramidase, and a fragment of the antibody. Item 3. The exosome production promoter according to Item 2, wherein the low molecular weight compound that inhibits the function of acid ceramidase is N-oleylethanolamine. Item 4. The exosome production promoter according to Item 1, wherein the substance capable of inhibiting the expression of acid ceramidase is selected from the group consisting of siRNA, shRNA, dsRNA, miRNA, and antisense nucleic acid against acid ceramidase. Item 5. The exosome production-promoting agent according to any one of Items 1 to 4, wherein the active ingredient does not suppress the expression of lysosome-associated transmembrane protein 4B. Item 6. The exosome production promoter according to any one of Items 1 to 5, which is a food or drink for promoting exosome production. Item 7. The exosome production promoter according to any one of Items 1 to 5, which is a pharmaceutical for promoting exosome production. Item 8. The exosome production promoter according to any one of Items 1 to 5, which is an agent for improving or preventing an amyloid β-related disease. Item 9. The exosome production promoter according to any one of Items 1 to 5, which is an agent for preventing or treating Alzheimer's disease. Effect of the Invention
[0016] According to the present invention, it is possible to efficiently promote exosome acidification by efficiently increasing endogenous ceramide. [Brief description of the drawings]
[0017] [Figure 1]The results show that suppression of acid ceramidase gene expression by siRNA promotes exosome production. The graph compares the amount of exosome production in the acid ceramidase gene expression suppression group (ASAH1 siRNA) with the amount of exosome production in the control group (CTRL), the LAPTM4B gene suppression group (LAPTM4B siRNA), and the acid ceramidase gene expression suppression and APTM4B gene suppression group (ASAH1 / LAPTM4B siRNA). [Diagram 2] This shows the results indicating the promotion of exosome production by an acid ceramidase inhibitor, and is a graph comparing the amount of exosome production by the acid ceramidase inhibitor-treated group (NOE) with the amount of exosome production by the control group (CTRL), the LAPTM4B gene-suppressed group (LAPTM4B siRNA), and the acid ceramidase inhibitor-treated and LAPTM4B gene-suppressed group (NOE / LAPTM4B siRNA). [Diagram 3] 1 is an image showing the intracellular localization pattern of long-chain fatty acid ceramide (C18:0 ceramide) by fluorescence in comparison with the presence pattern of short-chain fatty acid ceramide (C6:0 ceramide). [Figure 4] 1 is a graph showing the relationship between the chain length of externally added ceramide and the exosome production effect and the suppression of LAPTM4B expression. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] The present invention relates to an exosome production promoter that contains as an active ingredient a substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase. Hereinafter, embodiments of the exosome production promoter of the present invention will be described in detail.
[0019] Active ingredients The exosome production promoter of the present invention uses a substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase as an active ingredient. The substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase increases endogenous ceramide, promoting the production of exosomes. In a more specific mechanism by which exosome production is promoted, it is believed that the increase in ceramide stimulates lysosome-associated transmembrane protein 4B (LAPTM4B), which migrates precursor organelles toward the cell membrane (transfers them to the recycling pathway), thereby promoting the production of exosomes.
[0020] Acid ceramidase, also known as N-acylsphingosine deacylase (AC), is an enzyme that catalyzes the hydrolysis of ceramide to sphingosine and free fatty acids. Mature acid ceramidase is a protein of about 50 kDa that contains an α subunit (about 13 kDa) and a β subunit (about 40 kDa), and is produced by cleavage of the acid ceramidase precursor protein, which is the product of the Asah1 gene.
[0021] The substance capable of inhibiting the function of acid ceramidase is not particularly limited, as long as it is pharmacologic acceptable and can suppress the function of the target.The substance inhibiting the function of acid ceramidase includes, for example, a low molecular weight compound inhibiting the function of acid ceramidase, an antibody or a fragment thereof that specifically binds to acid ceramidase, and an aptamer that specifically binds to acid ceramidase.These substances may be used alone or in combination of two or more.
[0022] The low molecular weight compound that inhibits the function of acid ceramidase may be a known low molecular weight compound or a low molecular weight compound to be developed in the future, as long as it can inhibit the function of acid ceramidase. Examples of the low molecular weight compound include the following.
[0023] [ka]
[0025] [ka]
[0026] [ka]
[0027] [ka]
[0028] These low molecular weight compounds may be used alone or in combination of two or more. In one embodiment of the present invention, among these low molecular weight compounds, N-oleoylethanolamine is preferred.
[0029] The antibody that specifically binds to acid ceramidase may be either a monoclonal antibody or a polyclonal antibody, preferably a monoclonal antibody. The isotype of these antibodies is not particularly limited and may be any of IgG, IgM, IgA, etc., preferably IgG.
[0030] When the therapeutic agent according to one embodiment of the present invention is administered to humans, the antibody is preferably an antibody whose antigenicity in the human body is reduced, specifically, a fully human antibody, a humanized antibody, a mouse-human chimeric antibody, a chicken-human chimeric antibody, etc. Among these, fully human antibodies and humanized antibodies are more preferable.
[0031] The antibody fragment may be any fragment having at least a complementarity determining region (CDR) for specifically recognizing and binding to acid ceramidase. Specifically, the antibody fragment may be Fab, Fab', or the like. , F(ab')2, scFv, scFv-Fc, etc.
[0032] The antibodies and fragments thereof can be produced by genetic engineering in accordance with standard methods.
[0033] In addition, the substance capable of suppressing the expression of acid ceramidase is not particularly limited, as long as it is pharmacologic acceptable and can suppress the expression of acid ceramidase from DNA encoding acid ceramidase. The substance that suppresses the expression of acid ceramidase may be one that exerts an inhibitory effect on the expression of acid ceramidase at any stage, such as transcription, post-transcriptional regulation, translation, or post-translational modification of the gene (ASAH1 gene) encoding acid ceramidase. Specific examples of the substance that suppresses the expression of acid ceramidase include nucleic acid molecules that suppress the transcription of genes encoding acid ceramidase, such as decoy nucleic acids; RNA molecules or precursors thereof that have an RNA interference effect on the mRNA of acid ceramidase, such as siRNA, shRNA, and dsRNA; and nucleic acid drugs such as miRNA, antisense nucleic acids (antisense DNA, antisense RNA), and ribozymes that suppress the translation of the mRNA of acid ceramidase. These nucleic acid drugs may be used alone or in combination of two or more. In addition, the base sequences of these nucleic acid drugs can be appropriately designed by those skilled in the art using known methods based on the information on the base sequence of the gene encoding acid ceramidase. Among these nucleic acid drugs, from the viewpoint of ease of clinical application, etc., preferred are siRNA, shRNA, dsRNA, miRNA, and antisense nucleic acid, and more preferably siRNA.
[0034] In addition, when the nucleic acid molecule is an RNA molecule, it may be designed to be produced in vivo. Specifically, it may be a vector in which DNA encoding the RNA molecule is inserted into an expression vector for mammalian cells. Examples of such expression vectors include virus vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, herpes virus, and Sendai virus, and animal cell expression plasmids.
[0035] In the production of exosomes brought about by a substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase, it is believed that LAPTM4B is stimulated to bind to LAT1 and migrate precursor organelles toward the cell membrane (to the recycling pathway), and therefore in a preferred embodiment of the present invention, the substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase does not suppress the expression of LAPTM4B.
[0036] The ceramide that is increased by a substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase is a compound having a structure in which a fatty acid is amide-bonded to a sphingoid. In the ceramide that is increased by one embodiment of the present invention, the structure of the sphingoid portion is not particularly limited, but the number of carbon atoms of the sphingoid portion constituting the ceramide is 18. Specific examples of the structure of the sphingoid portion include 4-sphingenine (sphingosine), 4-hydroxysphinganine (phytosphingosine), 4-hydroxy-trans-8-sphingenine, 4-hydroxy-cis-8-sphingenine, sphinganine, trans-8-sphingenine, cis-8-sphingenine, trans-4-sphingenine, trans-4,trans-8-sphingadienine, trans-4,cis-8-sphingadienine, cis4-cis8-sphingadienine, cis4-trans8-sphingadienine, and the like. Among these, preferred are trans-4,cis-8-sphingadienine, cis4-cis8-sphingadienine, trans4-trans8-sphingadienine, cis4-trans8-sphingadienine, 4-hydroxy-cis-8-sphingenine, and 4-hydroxy-trans8-sphingenine.
[0037] The ceramides increased by the exosome production promoter in one embodiment of the present invention may be any ceramides that are decomposed by acid ceramidase, specifically, ceramides present in lysosomes where acid ceramidase is localized, more specifically, long-chain ceramides localized in lysosomes. Here, the long-chain ceramide refers to a ceramide in which the fatty acid bound to the sphingo moiety is a long-chain fatty acid, and the carbon number of such a long-chain fatty acid is 12 to 26 in a preferred embodiment of the present invention, 14 to 24 in another preferred embodiment, 16 to 22 in a further preferred embodiment, and 18 to 20 in a further preferred embodiment. The fatty acid may be any of saturated fatty acids, unsaturated fatty acids containing a carbon-carbon double bond and / or a carbon-carbon triple bond, and α-hydroxy fatty acids.
[0038] In the ceramides increased by the exosome production promoter in one embodiment of the present invention, specific examples of fatty acids bound to the sphingoid portion include dodecanoic acid (C12:0), tetradecanoic acid (C14:0), hexadecanoic acid (C16:0), octadecanoic acid (C18:0), icosanoic acid (C20:0), heneicosanoic acid (C21:0), docosanoic acid (C22:0), tricosanoic acid (C23:0), tetradocosanoic acid (C24:0), pentacosanoic acid (C25:0), hexadocosanoic acid (C26:0), heptacosanoic acid (C27:0), octadocosanoic acid (28:0), and cis-9-octadecenoic acid (C18:1). In the notation "CX:Y" shown in parentheses for the fatty acid, CX indicates the number of carbon atoms per molecule, and Y indicates the number of unsaturated bonds per molecule, for example, "C16:0" represents a fatty acid having 16 carbon atoms and 0 unsaturated bonds. Among these fatty acids, octadecanoic acid is preferable.
[0039] The content of the substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase in the exosome production promoter in one embodiment of the present invention is not particularly limited, as long as it is an effective amount that can increase ceramide in the body and promote the production of exosomes, and can be appropriately adjusted depending on the application, dosage form, administration form, etc.
[0040] Other added ingredients In addition to the above-mentioned active ingredient, the exosome production promoter in one embodiment of the present invention may contain other additive components depending on the dosage form within a range that does not impair the effects of the present invention. Examples of additive components that can be contained in the exosome production promoter of one embodiment of the present invention include water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, esters, plant extracts, water-soluble polymers, surfactants, metal soaps, alcohols, polyhydric alcohols, pH adjusters, antioxidants, UV absorbers, preservatives, fragrances, powders, thickeners, pigments, and chelating agents. These additive components may be used alone or in combination of two or more. The content of these additive components is appropriately set depending on the type of additive component used and the dosage form of the exosome production promoter of the present invention.
[0041] Dosage form, formulation, and use The dosage form of the exosome production promoter in one embodiment of the present invention is not particularly limited and may be any of solid, semi-solid, or liquid, and may be appropriately selected depending on the type, application, administration method, etc. of the exosome production promoter.
[0042] The method of administration of the exosome production promoter in one embodiment of the present invention is not particularly limited and may be appropriately selected depending on the type of disease to which it is applied, and may be systemic administration or local administration. Specific examples include oral, intravascular (intraarterial or intravenous), transdermal, enteral, pulmonary, intranasal, intraventricular, and intramedullary administration. Intravascular administration also includes intravascular injection and continuous infusion.
[0043] The formulation of the exosome production promoter in one embodiment of the present invention is not particularly limited and can be appropriately set to a formulation suitable for the administration method, and examples of the formulation include any formulation such as tablets, capsules, granules, powders, syrups, injections, drips, nasal drops, infusions, infusions, suppositories, etc. For example, specific examples of the exosome production promoter in one embodiment of the present invention include foods, beverages, and pharmaceuticals.
[0044] When the exosome production promoter in one embodiment of the present invention is formulated as a food or drink, the exosome production promoter may be prepared as it is, in combination with other food materials or additives, or in combination with a delivery technique corresponding to oral administration, into a desired form. Examples of such food or drink include general food or drink, as well as specific health foods, nutritional supplements, functional foods, and foods for sick people. The form of these food or drink is not particularly limited, but specifically includes supplements such as capsules (soft capsules, hard capsules), tablets, granules, powders, jellies, and liposome preparations; beverages such as nutritional drinks, fruit juice drinks, carbonated drinks, and lactic acid drinks; and luxury items such as dumplings, ice cream, sherbet, gummy candy, and candy. Among these food or drink, beverages and supplements are preferable, and beverages and capsules are more preferable.
[0045] When the exosome production promoter in one embodiment of the present invention is formulated into a pharmaceutical formulation, the exosome production promoter may be prepared into a desired form as is, in combination with other additive components, or in combination with a delivery technique according to the dosage form. Specific examples of such pharmaceuticals include drinks, capsules (soft capsules, hard capsules), tablets, granules, powders, jellies, syrups, liposome preparations, injections, drips, nasal drops, infusions, infusions, suppositories, and the like.
[0046] Furthermore, when the exosome production promoter according to one embodiment of the present invention is formulated as a pharmaceutical product and a nucleic acid molecule is used as an active ingredient, it is desirable that the active ingredient is formulated together with a nucleic acid transfer aid, such as lipofectamine, oligofectamine, RNAifect, liposomes, polyamines, DEAE dextran, calcium phosphate, and dendrimers.
[0047] The dosage of the exosome production promoter in one embodiment of the present invention may be appropriately set within a range in which the expression of the target molecule can be suppressed and / or the function of the target molecule can be inhibited, depending on the type of active ingredient used, the severity of the patient's symptoms, the sex, age, etc.
[0048] The exosome production promoter in one embodiment of the present invention can be applied to diseases whose symptoms are alleviated or improved based on the promotion of exosome production. For example, since exosomes can suppress the accumulation of amyloid β protein, which is one of the causes of Alzheimer's disease, it is considered that promoting the production of exosomes can suppress the onset of Alzheimer's disease and alleviate the symptoms. In other words, the exosome production promoter in one embodiment of the present invention can suppress the onset of Alzheimer's disease and alleviate the symptoms. In this way, the exosome production promoter in one embodiment of the present invention can also be suitably applied as an Alzheimer's disease preventive agent. In particular, since a person who has a relative who has developed familial Alzheimer's disease but has not developed familial Alzheimer's disease is required to prevent familial Alzheimer's disease on a daily basis, the exosome production promoter in one embodiment of the present invention is suitably applied to such a person who is at risk of developing familial Alzheimer's disease.
[0049] Other diseases whose symptoms can be improved by promoting exosome production include, for example, neurodegenerative diseases such as Parkinson's disease, frontotemporal degeneration, and polyglutamine disease.
[0050] As described above, an exosome production promoter containing as an active ingredient a substance capable of inhibiting the function and / or suppressing the expression of acid ceramidase can promote the production of exosomes. The exosome production promoter in one embodiment of the present invention can be used for the treatment or prevention of diseases whose symptoms are improved by promoting the production of exosomes. Specifically, for example, the exosome production promoter in one embodiment of the present invention can be used for the prevention or treatment of neurodegenerative diseases such as Alzheimer's disease (including familial Alzheimer's disease), Parkinson's disease, frontotemporal degeneration, and polyglutamine disease. EXAMPLES
[0051] The present invention will be described in more detail below with reference to examples, but each configuration and their combinations in each embodiment are merely examples, and addition, omission, substitution, and other modifications of the configurations are possible as appropriate within the scope of the present invention. The present invention is not limited to the embodiments, but is limited only by the scope of the claims.
[0052] [Test Example 1: Promotion of exosome production by suppressing acid ceramidase gene expression with siRNA] (1) Human neuroblastoma-derived SH-SY5Y cells were used as culture cells. The cells were cultured in a 12-well plate at a cell density of 1.0x10 5 SH-SY5Y cells were seeded at 10 cells / well and cultured overnight at 37°C.
[0053] (2) After culturing, each siRNA was introduced using the lipofection method with Lipofectamine RNAiMAX (ThermoFisher). In the acid ceramidase gene expression suppression group (ASAH1 siRNA), ASAH1 (ID: s497:Silencer (R)Select Pre-designed siRNA (ThermoFisher) was used at a final concentration of 10 nM and cultured at 37°C for 24 hours. In the control group (CTRL), Stealth RNAi TM siRNA negative control med GC (ThermoFisher) was used at the same concentration as above and cultured at 37°C for 24 hours. In the LAPTM4B gene suppression group (LAPTM4B siRNA), LAPTM4B (ID: s30810:Silencer (R) Select Pre-designed siRNA (ThermoFisher) was used at the same concentration as above, and the cells were cultured at 37° C. for 24 hours. In the acid ceramidase gene expression suppression and APTM4B gene suppression group (ASAH1 / LAPTM4B siRNA), the above-mentioned ASAH1 and LAPTM4B were used as siRNA at the same concentrations as above, and the cells were cultured at 37° C. for 24 hours.
[0054] (3) After the incubation, the medium was replaced with serum-free medium and the cells were further incubated for 24 hours. (4) After the culture, the culture supernatant was collected and the exosomes in the culture supernatant were collected as a sediment by ultracentrifugation. The ultracentrifugation was performed three times at 2,000 x g for 10 minutes, 10,000 x g for 30 minutes, and 100,000 x g for 70 minutes.
[0055] (5) Using the Human PS Capture Exosome ELISA Kit (Fujifilm Wako Co., Ltd.), the amount of exosomes recovered from each of the control group (CTRL), acid ceramidase gene expression inhibition group (ASAH1 siRNA), LAPTM4B gene inhibition group (LAPTM4B siRNA), and acid ceramidase gene expression inhibition and APTM4B gene inhibition groups (ASAH1 / LAPTM4B siRNA) was measured. The amount of exosomes was measured by absorbance. (6) The amount of exosomes obtained as absorbance was quantified (%CTRL) with the average absorbance in the control group (CTRL) set at 100% and graphed. The results are shown in Figure 1.
[0056] As is clear from Figure 1, suppressing the expression of the acid ceramidase gene promoted exosome production. On the other hand, suppressing the expression of the LAPTM4B gene did not have the effect of promoting exosome production, and even if the expression of the acid ceramidase gene was suppressed, the effect of promoting exosome production was not obtained if the expression of the LAPTM4B gene was suppressed. In other words, it was shown that the presence of LAPTM4B is involved in the promotion of exosome production by suppressing the expression of the acid ceramidase gene.
[0057] [Test Example 2: Promotion of exosome production by acid ceramidase inhibitors] (1) Human neuroblastoma-derived SH-SY5Y cells were used as culture cells. The cells were cultured in a 12-well plate at a cell density of 1.0x10 5 SH-SY5Y cells were seeded at 10 cells / well and cultured overnight at 37°C.
[0058] (2) After the culture, in the LAPTM4B gene suppression group (LAPTM4B siRNA) and the acid ceramidase inhibitor treatment and LAPTM4B gene suppression group (NOE / LAPTM4B siRNA), LAPTM4B (ID: s30810:Silencer (R) Select Pre-designed siRNA (ThermoFisher) was used at a final concentration of 10 nM and the cells were cultured at 37°C for 24 hours.
[0059] (3) After the culture, the medium was replaced with a serum-free medium. Furthermore, in the acid ceramidase inhibitor treatment group (NOE) and the acid ceramidase inhibitor treatment and LAPTM4B gene suppression group (NOE / LAPTM4B siRNA), the acid ceramidase inhibitor NOE (N-oleylethanolamine, Sigma) was added to a concentration of 50 μM, and the cells were further cultured at 37° C. for 24 hours. In the control group (CTRL), the cells were cultured in the same manner, except that neither siRNA nor the acid ceramidase inhibitor was added throughout steps (2) and (3).
[0060] (4) After the culture, the culture supernatant was collected and the exosomes in the culture supernatant were collected as a sediment by ultracentrifugation. The ultracentrifugation was performed three times at 2,000 x g for 10 minutes, 10,000 x g for 30 minutes, and 100,000 x g for 70 minutes.
[0061] (5) Using the Human PS Capture Exosome ELISA Kit (Fujifilm Wako Co., Ltd.), the amount of exosomes recovered from each of the control group (CTRL), acid ceramidase inhibitor treatment group (NOE), LAPTM4B gene suppression group (LAPTM4B siRNA), and acid ceramidase inhibitor treatment and LAPTM4B gene suppression group (NOE / LAPTM4B siRNA) was measured. The amount of exosomes was measured by absorbance. (6) The amount of exosomes obtained as absorbance was quantified (%CTRL) with the average absorbance in the control group (CTRL) set at 100% and graphed. The results are shown in Figure 2.
[0062] As is clear from Figure 2, exosome production was promoted by inhibiting the function of acid ceramidase. On the other hand, suppressing the expression of the LAPTM4B gene did not have the effect of promoting exosome production, and even if the function of acid ceramidase was inhibited, the effect of promoting exosome production was not obtained when the expression of the LAPTM4B gene was suppressed. In other words, it was shown that the presence of LAPTM4B is involved in the promotion of exosome production by inhibiting the function of acid ceramidase.
[0063] [Test Example 3: Localization of long-chain fatty acid ceramide] The cultured cells were cultured in the same manner as in Test Examples 1 and 2. After the culture, C18 ceramide (d18:1 / 18:0) or C6 ceramide (d18:1 / 6:0) (both manufactured by Avanti Polar Lipids) labeled with green fluorescence by nitrobenzoxadiazole was added to the medium at a concentration of 5 μM, and the lysosome-labeling fluorescent dye LysoTracker Red DND-99 (ThermoFisher Scientific) was also added to the medium, followed by further culturing at 37° C. for 30 minutes. After that, a fluorescent image was obtained using a fluorescent microscope Keyence BZ-X710. The obtained fluorescent image is shown in FIG. 3.
[0064] As is clear from Figure 3, the long-chain fatty acid ceramide (C18:0 ceramide) was observed to be localized in lysosomes, whereas the short-chain fatty acid ceramide (C6:0 ceramide) was not localized in such a manner. Considering that the acid ceramidase that caused the promotion of exosome production observed in Test Examples 1 and 2 was localized in lysosomes, the excellent promotion of exosome production observed in Test Examples 1 and 2 by functional inhibition or expression suppression of acid ceramidase is the result of efficiently increasing ceramide by selecting localized long-chain fatty acid ceramide rather than non-localized short-chain fatty acid ceramide as the endogenous ceramide to be increased, and can be said to be a unique effect of selecting acid ceramidase as the target for functional inhibition or expression suppression.
[0065] [Test Example 4: Relationship between externally added ceramide chain length and exosome production effect and LAPTM4B expression inhibition] The cells were cultured in the same manner as in Test Examples 1 and 2. After the culture, the cells were divided into a LAPTM4B siRNA-treated group (LAPTM4B siRNA) and a control siRNA-treated group (Cont siRNA), and each group was added with 10 μM of various ceramides described below, followed by further culturing at 37° C. for 24 hours.
[0066] (Added ceramide) Pig brain derived ceramide; Avanti Polar Lipids Synthetic C2 ceramide d18:1 / 2:0; Avanti Polar Lipids Synthetic C6 ceramide d18:1 / 6:0; manufactured by Avanti Polar Lipid Synthetic C16 ceramide d18:1 / 16:0; Avanti Polar Lipids Synthetic C18 ceramide d18:1 / 18:0; Avanti Polar Lipids Synthetic C24 ceramide d18:1 / 24:0; Avanti Polar Lipids
[0067] After culturing, the culture supernatant was collected and ultracentrifuged to collect exosomes in the culture supernatant as a sediment. Ultracentrifugation was performed three times at 2,000xg for 10 minutes, 10,000xg for 30 minutes, and 100,000xg for 70 minutes. The amount of exosomes collected from each group was measured using a Human PS Capture Exosome ELISA Kit (Fujifilm Wako Co., Ltd.). The amount of exosomes was measured by absorbance. The measurement results are shown in Figure 4.
[0068] From FIG. 4, the relationship between the chain length of externally added ceramide and the exosome production effect and the suppression of LAPTM4B expression can be understood. As is clear from FIG. 4, it is recognized that LAPTM4B is involved in exosome production by ceramide, and in particular, the increase in the amount of exosome production compared to the case where LAPTM4B expression was suppressed was remarkable in the case of long-chain fatty acid ceramide (C16:0 ceramide, C18:0 ceramide). Considering that LAPTM4B is localized in lysosomes like acid ceramidase, the excellent promotion of exosome production by functional inhibition or expression suppression of acid ceramidase observed in Test Examples 1 and 2 is the result of efficiently increasing ceramide by selecting long-chain fatty acid ceramide that is strongly related to LAPTM4B for increasing exosomes as the endogenous ceramide to be increased, and it can be said that this is a unique effect due to the selection of acid ceramidase as the target of functional inhibition or expression suppression.
Claims
1. An exosome production promoter having an acid ceramidase inhibitor and / or an acid ceramidase gene expression inhibitor as active ingredients, and not containing a component that inhibits the expression of lysosome-associated transmembrane protein 4B.
2. the acid ceramidase inhibitor is at least one selected from the group consisting of a low molecular weight compound that inhibits the function of acid ceramidase, an antibody against acid ceramidase, and a fragment of the antibody; The exosome production promoter according to claim 1, wherein the low molecular weight compound that inhibits the function of acid ceramidase is one or more of N-oleylethanolamine, selanib 1, selanib 2, and a low molecular weight compound represented by the following formula: [Formula 1] [chemical 2]
3. The exosome production promoter according to claim 2, wherein the low molecular weight compound that inhibits the function of acid ceramidase is N-oleylethanolamine.
4. The exosome production promoter according to claim 1 , wherein the acid ceramidase gene expression inhibitor is selected from the group consisting of siRNA, shRNA, dsRNA, miRNA, and antisense nucleic acid against acid ceramidase.
5. The exosome production promoter according to any one of claims 1 to 4, which is a food or drink for promoting exosome production.
6. The exosome production promoter according to any one of claims 1 to 4, which is a pharmaceutical for promoting exosome production.
7. The exosome production promoter according to any one of claims 1 to 4, which is an agent for improving or preventing an amyloid β-related disease.
8. The exosome production promoter according to any one of claims 1 to 4, which is a preventive or therapeutic agent for Alzheimer's disease.
Citation Information
Patent Citations
Methods and compositions for cancer treatment
JP2012502954A
Amyloid beta aggregation depressant
JP2014224132A
Aggregation-inhibiting composition for amyloid β protein
JP2016124865A
Inhibitors which inhibit amyloid fiber formation, decomposers which disassemble amyloid fibers, medicaments for prevention, therapy, or progressive inhibition of neurodegenerative disease, and production methods of inhibitor and decomposer
JP2016145175A
Exosome production promoting agent
JP2018150290A
